SNP information rs1057910

Research and publications:

  8873220   The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

  9352571   Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

  9630825   Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.

  10073515   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

  10208645   Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

  10509530   CYP2C9*3 allelic variant and bleeding complications.

  10961881   Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

  11127854   Genetic modulation of oral anticoagulation with warfarin.

  11337938   In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.

  11692083   Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

  12893985   Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

  14707031   Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use.

  15116053   Pharmacogenetics of acenocoumarol pharmacodynamics.

  15805193   Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin

  16153401   Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient.

  16385451   A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.

  16432637   Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.

  17048007   Association of warfarin dose with genes involved in its action and metabolism

  17111199   Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

  17368604   The association of CYP2C9 gene polymorphisms with colorectal carcinoma in Han Chinese.

  17387222   Genetic-based dosing in orthopedic patients beginning warfarin therapy.

  17681167   Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.

  18030307   Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients.

  18305455   Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

  18466099   Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

  18535201   A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.

  18542936   VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.

  18547414   Genotyping panel for assessing response to cancer chemotherapy

  18574025   The largest prospective warfarin-treated cohort supports genetic forecasting

  18596683   Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

  18662264   Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

  18680736   Genetic factors contribute to patient-specific warfarin dose for Han Chinese.

  18752379   Warfarin pharmacogenetics.

  18936436   Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994

  18990750   Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk.

  18992263   Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways

  19177029   Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients.

  19223558   Polymorphic variation in NFKB1 and other aspirin-related genes and risk of Hodgkin lymphoma.

  19228618   Estimation of the warfarin dose with clinical and pharmacogenetic data.

  19300499   A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

  19376514   Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.

  19387626   Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin.

  19422321   Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

  19538716   Genetic risk factors for thrombosis and pharmacogenetic variants of warfarin in a healthy population of San Miguel (Azores).

  19617466   CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity

  19679631   Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

  19694740   No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

  19794411   Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.

  19874474   Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

  19955245   Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

  20017677   ARMS test for diagnosis of CYP2C9 and VKORC1 mutation in patients with pulmonary embolism in Han Chinese.

  20072124   Genetic and clinical predictors of warfarin dose requirements in African Americans.

  20082485   Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women

  20149073   Pharmacogenetics of acenocoumarol in patients with extreme dose requirements.

  20150829   Cytochrome P450 2C9-CYP2C9.

  20175863   The genetics of ischaemic stroke.

  20203262   Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.

  20214591   Pharmacogenomics in aspirin intolerance.

  20459744   Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.

  20555338   Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.

  20585445   A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants.

  20653676   CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

  20709439   Warfarin dosing in patients with impaired kidney function.

  20716240   New genetic variant that might improve warfarin dose prediction in African Americans.

  20733952   Warfarin genotyping using three different platforms.

  20808793   Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants?

  20833980   In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.

  20842355   VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.

  20847277   Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification.

  20854800   Genotyping three SNPs affecting warfarin drug response by isothermal real-time HDA assays.

  20921971   Mapping genes that predict treatment outcome in admixed populations.

  20936101   Pharmacogenetics of Anti-Diabetes Drugs.

  20937634   Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk.

  21110013   Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.

  21110192   Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.

  21127708   Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction.

  21132113   Direct-to-Consumer Genetic and Genomic Testing: Preparing Nurse Practitioners for Genomic Healthcare.

  21148049   Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.

  21219403   Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial.

  21228733   Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.

  21270790   The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

  21320153   Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.

  21383771   Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia.

  21428770   Genomics and drug response.

  21441355   Detection of common single nucleotide polymorphisms synthesizing quantitative trait association of rarer causal variants.

  21450715   High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans.

  21480951   Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients.

  21532843   Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk.

  21562147   Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

  21575037   Population diversity and the performance of warfarin dosing algorithms.

  21639946   Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.

  21691466   Genetics of warfarin sensitivity in an emergency department population with thromboembolic.

  21708280   Candidate gene studies in gallbladder cancer: a systematic review and meta-analysis

  21803011   Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome.

  21883387   Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.

  21900891   Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.

  21918509   Pharmacogenomics: application to the management of cardiovascular disease.

  22010099   VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.

  22023024   The pharmacogenetics of the response to warfarin in Chinese.

  22114699   Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation.